Objective This post hoc analysis assessed the predictive value of improvement in
depressive scores at early time points for treatment outcomes at week 8 in patients with …

Considerations when selecting a first-line anti-depressant agent include the potential for
achieving greater response with increasing dosages, thereby allowing greater flexibility in …

Venlafaxine is a commonly used antidepressant with both serotonergic and noradrenergic
activity. There are concerns that it may prolong the corrected QT interval (QTc), and older …

Background Cardiovascular side effects from antidepressant drugs, including clinically
significant blood pressure changes, conduction disturbances, and arrhythmias may …

Background: Quantifying efficacy and safety differences between drugs is difficult because
rigorous statistical methods to assess benefit and risk simultaneously are lacking. Methods …

The comparative bioavailability of the novel antidepressant venlafaxine and its
pharmacologically active metabolite O‐desmethylvenlafaxine was assessed when …

Objective Meta-analysis of all available trials of Venlafaxine in the treatment of major
depressive disorders, including treatment resistant depression and long-term relapse …

The aim of this study was to assess antidepressant efficacy and safety of venlafaxine
extended release in Japanese patients with major depressive disorder (MDD). We carried …

BackgroundIt had been suggested that the antidepressant venlafaxine, which inhibits
reuptake of both serotonin and (at higher doses) noradrenaline, may result in better …

Introduction: To assess the efficacy of desvenlafaxine (administered as desvenlafaxine
succinate) in outpatients with major depressive disorder. Methods: A meta-analysis of …